Cargando…
Infliximab enhances the therapeutic effects of 5-fluorouracil resulting in tumor regression in colon cancer
Colon cancer (CC) is among the most common malignant diseases with a dismal survival. Tumor necrosis factor-alpha (TNF-α) has been identified as a therapeutic target in various cancers, and anti-TNF-α treatment has shown promising effects in different cancer models. However, if TNF-α can be targeted...
Autores principales: | Liu, Fen, Ai, Feiyan, Tian, Li, Liu, Shaojun, Zhao, Lian, Wang, Xiaoyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055041/ https://www.ncbi.nlm.nih.gov/pubmed/27757041 http://dx.doi.org/10.2147/OTT.S109342 |
Ejemplares similares
-
Oxaliplatin and infliximab synergize to induce regression of colon cancer
por: Huang, Di, et al.
Publicado: (2018) -
Oxaliplatin and Infliximab Combination Synergizes in Inducing Colon Cancer Regression
por: Li, Wenya, et al.
Publicado: (2017) -
Integrative Proteo-Genomic Analysis for Recurrent Survival Prognosis in Colon Adenocarcinoma
por: Ai, FeiYan, et al.
Publicado: (2022) -
miR-107 Promotes Proliferation and Inhibits Apoptosis of Colon Cancer Cells by Targeting Prostate Apoptosis Response-4 (Par4)
por: Liu, Fen, et al.
Publicado: (2017) -
Metformin Enhancement of Therapeutic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells and Nude Mice
por: Yip, Kwan-Ling, et al.
Publicado: (2022)